PainTEQ Welcomes Lalit Venkatesan, PhD as Senior VP of Clinical Research
In an important leadership move, PainTEQ, a prominent medical device company headquartered in Tampa, Florida, has announced the appointment of Dr. Lalit Venkatesan as the Senior Vice President of Clinical Research. This strategic promotion is expected to significantly bolster the company's initiatives aimed at advancing minimally invasive therapies for sacroiliac (SI) joint dysfunction.
Dr. Venkatesan brings with him a wealth of expertise, having accumulated over a decade of experience in the fields of neuromodulation and medical device innovation. His background encompasses clinical strategy and scientific engagement, making him a valuable asset for PainTEQ as the company continues to expand its portfolio in the minimally invasive SI joint technology sector.
"PainTEQ presents a unique opportunity to redefine the study and treatment of SI joint dysfunction," Dr. Venkatesan remarked. He expressed enthusiasm in joining PainTEQ’s dedicated team, underscoring his commitment to establishing a robust and transparent framework of clinical evidence that informs physicians and enhances patient outcomes.
Previously, Dr. Venkatesan held the position of Senior Director of Global Medical Affairs at Saluda Medical. During his tenure, he played a pivotal role in advancing closed-loop spinal cord stimulation research, a feat that highlights his capacity for innovative thinking in medical technology. Additionally, he has held leadership roles with significant responsibilities at Abbott Neuromodulation and Natus Medical, where he contributed to various clinical programs focused on chronic pain management and movement disorders.
His impressive contributions to the field have earned him several accolades, including the Volwiler Society Fellowship and the Abbott Chairman's Award. He has also gained recognition in Business Insider's list of "30 Under 40 MedTech Healthcare Leaders."
Dr. Corey Hunter, an Assistant Professor in the Department of Physical Medicine and Rehabilitation at Montefiore Medical Center, praised Dr. Venkatesan, stating, "His scientific rigor and strategic leadership will undoubtedly advance credible clinical evidence in SI joint dysfunction." This sentiment reflects the broader expectations within the medical community regarding the potential impact of Dr. Venkatesan’s leadership at PainTEQ.
The company is optimistic about the future under his guidance, with Chief Executive Officer Shanth Thiyagalingam stating, "We are thrilled to welcome Lalit to our leadership team. His expertise in global clinical research and evidence strategies is vital as we continue investing in clinical science and ensuring the responsible adoption of our minimally invasive SI joint therapies.”
Founded in 2013, PainTEQ's mission centers around developing innovative solutions for interventional pain management, particularly in treating back pain and SI joint dysfunction. With a proprietary SI joint implant system that has already been utilized in over 14,000 procedures, the company is committed to providing patients with effective, minimally invasive options that truly alleviate chronic pain.
As Dr. Venkatesan steps into this vital role at PainTEQ, the industry watches with anticipation to see how his leadership will drive forward the company’s clinical research initiatives, ultimately aiming to produce meaningful advancements in the treatment of SI joint dysfunction. This appointment is not only a testament to Dr. Venkatesan’s abilities but also reflects PainTEQ’s commitment to pushing the boundaries of current medical practices and delivering significant benefits to physicians and patients alike.
Dr. Venkatesan brings with him a wealth of expertise, having accumulated over a decade of experience in the fields of neuromodulation and medical device innovation. His background encompasses clinical strategy and scientific engagement, making him a valuable asset for PainTEQ as the company continues to expand its portfolio in the minimally invasive SI joint technology sector.
"PainTEQ presents a unique opportunity to redefine the study and treatment of SI joint dysfunction," Dr. Venkatesan remarked. He expressed enthusiasm in joining PainTEQ’s dedicated team, underscoring his commitment to establishing a robust and transparent framework of clinical evidence that informs physicians and enhances patient outcomes.
Previously, Dr. Venkatesan held the position of Senior Director of Global Medical Affairs at Saluda Medical. During his tenure, he played a pivotal role in advancing closed-loop spinal cord stimulation research, a feat that highlights his capacity for innovative thinking in medical technology. Additionally, he has held leadership roles with significant responsibilities at Abbott Neuromodulation and Natus Medical, where he contributed to various clinical programs focused on chronic pain management and movement disorders.
His impressive contributions to the field have earned him several accolades, including the Volwiler Society Fellowship and the Abbott Chairman's Award. He has also gained recognition in Business Insider's list of "30 Under 40 MedTech Healthcare Leaders."
Dr. Corey Hunter, an Assistant Professor in the Department of Physical Medicine and Rehabilitation at Montefiore Medical Center, praised Dr. Venkatesan, stating, "His scientific rigor and strategic leadership will undoubtedly advance credible clinical evidence in SI joint dysfunction." This sentiment reflects the broader expectations within the medical community regarding the potential impact of Dr. Venkatesan’s leadership at PainTEQ.
The company is optimistic about the future under his guidance, with Chief Executive Officer Shanth Thiyagalingam stating, "We are thrilled to welcome Lalit to our leadership team. His expertise in global clinical research and evidence strategies is vital as we continue investing in clinical science and ensuring the responsible adoption of our minimally invasive SI joint therapies.”
Founded in 2013, PainTEQ's mission centers around developing innovative solutions for interventional pain management, particularly in treating back pain and SI joint dysfunction. With a proprietary SI joint implant system that has already been utilized in over 14,000 procedures, the company is committed to providing patients with effective, minimally invasive options that truly alleviate chronic pain.
As Dr. Venkatesan steps into this vital role at PainTEQ, the industry watches with anticipation to see how his leadership will drive forward the company’s clinical research initiatives, ultimately aiming to produce meaningful advancements in the treatment of SI joint dysfunction. This appointment is not only a testament to Dr. Venkatesan’s abilities but also reflects PainTEQ’s commitment to pushing the boundaries of current medical practices and delivering significant benefits to physicians and patients alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.